Sugi Predict

Sugi Predict / Compounds / SCHEMBL194101

SCHEMBL194101

SCHEMBL194101

COC(=O)NC(C)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 2/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ACE P12821 1/20 0.41
▸ CPA1 P15085 1/20 0.41
▸ ACE2 Q9BYF1 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ TGFBR1 P36897 1/20 0.39
▸ TYR P14679 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ TP53 P04637 1/20 0.36
▸ TSHR P16473 2/20 0.36
▸ CA2 P00918 2/20 0.35
▸ CA1 P00915 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444915 1.00 MME (0.41) MMERAB9AACECPA1ACE2
SCHEMBL194100 1.00 MME (0.41) MMERAB9AACECPA1ACE2
SCHEMBL7324309 0.91 MME (0.44) MMERAB9AACECPA1ACE2
Alanine SCHEMBL2176579 0.91 MME (0.36) MMERAB9AACECPA1ACE2
SCHEMBL7324302 0.91 MME (0.44) MMERAB9AACECPA1ACE2
SCHEMBL204822 0.87 SMN1; SMN2 (0.40) SMN1; SMN2TYRALDH1A1CA2CA1
SCHEMBL29613052 0.81 MME (0.41) MMEACECPA1ACE2SMN1; SMN2
Aspartic Acid SCHEMBL7173783 0.81 SLC7A5 (0.42) —
SCHEMBL23766673 0.80 HTT (0.43) MMERAB9AACECPA1ACE2
SCHEMBL3507245 0.80 TGFBR1 (0.55) MMERAB9AACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024017317-A1 HER2 TARGETING PEPTIDE MOLECULE AND USE THEREOF 中国科学院上海药物研究所 2024-01-25 — — WO claimed
WO-2009151744-A1 S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES GALLEON PHARMACEUTICALS, INC. (US) 2009-12-17 — — WO claimed
US-12496282-B2 Hepatitis B antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2025-12-16 — — US disclosed
US-20250122219-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-17 — — US disclosed
WO-2025080863-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-04-17 — — WO disclosed
US-20240366538-A1 Hepatitis B Antiviral Agents ENANTA PHARM INC (US) 2024-11-07 — — US disclosed
US-12011425-B2 Hepatitis B antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2024-06-18 — — US disclosed
WO-2024043313-A1 REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY 三菱ケミカル株式会社 2024-02-29 — — WO disclosed
US-20230241012-A1 HEPATITIS B ANTIVIRAL AGENTS ENANTA PHARM INC (US) 2023-08-03 — — US disclosed
EP-4196228-A1 N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF Albert Einstein College of Medicine (US) 2023-06-21 — — EP disclosed
US-11596611-B2 Hepatitis B antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2023-03-07 — — US disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 — — WO disclosed
US-20050096397-A1 Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine NORGINE EUROPE BV (NL) 2005-05-05 — — US disclosed
EP-1458370-A1 TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R,2S-METHOXAMINE Norgine Europe BV (NL) 2004-09-22 — — EP disclosed
WO-2003055474-A1 TREATMENT OF FAECAL INCONTINENCE AND OTHER CONDITIONS WITH 1R, 2S-METHOXAMINE NORGINE EUROPE BV (NL) 2003-07-10 — — WO disclosed
US-5466858-A Ruthenium catalyst, high selectivity with a carboxylic acid UBE INDUSTRIES, LTD. (JP) 1995-11-14 — — US disclosed
US-5079167-A Enzymatic resolution of amino acid carbamate racemates GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) 1992-01-07 — — US disclosed
EP-0243606-A1 Process for enzymatic racemate cleavage Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) 1987-11-04 — — EP disclosed
WO-1987005329-A1 PROCESS FOR THE SEPARATION OF RACEMATES GESELLSCHAFT FÜR BIOTECHNOLOGISCHE FORSCHUNG MBH ( (DE) 1987-09-11 — — WO disclosed
US-4618710-A Preparation of optically active ketones THE REGENTS OF THE UNIVERSITY OF CALIF. (US) 1986-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596611-B2 Hepatitis B antiviral agents HAVCR2, PYGL, SLC10A1 MME 1280/4885RAB9A 969/4885ACE 495/4885
US-20250122219-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DPYD MME 2896/4885RAB9A 1147/4885ACE 203/4885
US-20050096397-A1 Treatment of faecal incontinence and other conditions with 1r,2s-methoxamine HTR1D, MTNR1A, ADRA1D MME 220/4885RAB9A 2001/4885ACE 855/4885
US-20230241012-A1 HEPATITIS B ANTIVIRAL AGENTS HAVCR2, PYGL, SLC10A1 MME 1280/4885RAB9A 969/4885ACE 495/4885
US-12011425-B2 Hepatitis B antiviral agents HAVCR2, PYGL, SLC10A1 MME 1280/4885RAB9A 969/4885ACE 495/4885
US-20240366538-A1 Hepatitis B Antiviral Agents HAVCR2, PYGL, SLC10A1 MME 1280/4885RAB9A 969/4885ACE 495/4885
US-12496282-B2 Hepatitis B antiviral agents HAVCR2, PYGL, SLC10A1 MME 1280/4885RAB9A 969/4885ACE 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.